CORZ Stock Forecast & Price Target

Core Scientific is supported by a rare combination of execution credibility, contracted cash flow visibility, and a growing power pipeline, with management delivering another 48 MW and staying on track for the full 590 MW CoreWeave contract in early 2027. Its balance sheet is strong, including about $2B in unrestricted cash and $4.3B raised so far this year, while the CRWV lease alone is expected to generate roughly $600M of NOI in 2027 and help fund expansion into AMD and other HPC opportunities. The company also has ~2.6GW of approved power capacity, about 385MW of grid-connected leasable capacity, and a diversified footprint that supports incremental contracts, making the stock look undervalued relative to its AI/HPC growth runway.

Core Scientific is facing a fundamentally weaker outlook because delays in bringing power infrastructure online for CRWV and AMD could defer full run-rate revenues and slow the ramp of its high-density colocation business. The downside case also assumes difficulty securing incremental power approvals, which would limit HPC scaling and leave the company overly dependent on its existing CRWV contract rather than diversifying its revenue base. Additional pressure comes from possible BTC mining fleet liquidation write-downs, financing constraints for further data center buildouts, poorly executed M&A, and dilutive equity raises, all of which could erode value and weaken the balance sheet.